Reforming India's Healthcare Margin and Pricing Policy
Moving beyond MRP to a value-based pricing model for medical products.
1The MRP Pricing Trap
The current Maximum Retail Price system in India often fails to protect patients, as it frequently becomes the default charge rather than a ceiling. Recent incidents, such as a product purchased for ₹11 being billed at ₹325, highlight the lack of transparency regarding supply chain margins and actual hospital procurement costs.
2Beyond Uniform Price Controls
While the 2019 trade-margin rationalization for cancer medicines saved an estimated 200 crore annually, a blanket approach is insufficient. India must distinguish between routine, high-volume commodities and breakthrough therapies. A standard syringe should not command the same return as a complex drug developed through years of rigorous clinical research and trials.
3Differential Profit Strategy
A tiered margin strategy is essential for a sustainable healthcare ecosystem. Routine products should have transparent, modest margins based on procurement prices. Conversely, companies taking significant scientific risks in rare disease research deserve higher returns. This ensures that premiums reward genuine clinical value creation rather than just aggressive marketing or brand positioning.
4Defining Clinical Value
Novelty claims must be rigorously tested against existing treatments to justify higher prices. A product is only valuable if it demonstrably improves patient outcomes, prevents complications, or lowers total system costs over time. Products that reduce repeated hospital admissions provide better long-term value than the cheapest item currently available on the shelf.
5Proposed Pricing Panel
India should establish an independent Healthcare Pricing and Value Panel to evaluate products based on clinical benefit and research risk. This body would include clinicians, scientists, and health economists to ensure decisions are evidence-based. Members must disclose conflicts of interest and provide a clear appeal process for all stakeholders involved in pricing.
6Linking Returns to Obligations
Higher profit margins for pharmaceutical companies should come with enforceable obligations. Agreements could link payments to observed patient outcomes, ensuring that promised benefits are realized. Concessional access for vulnerable populations must be mandatory rather than left to corporate goodwill, ensuring that breakthrough innovations remain accessible to those who need them most.
7Transparency in Billing
Regulators must separate manufacturer profits from hospital and trade margins to prevent downstream inflation. Patients deserve itemized bills that clearly distinguish between product charges and handling fees. Simultaneously, policies must remain sensitive to the needs of small, rural pharmacies to ensure they remain viable and continue providing essential medical supplies locally.
8Redefining Fair Pricing
The ultimate goal is to protect families from excessive costs while incentivizing medical breakthroughs. By shifting from a rigid MRP-focused model to one based on proven value and equitable access, India can balance commercial viability with public health. Margin must follow patient benefit, not the bargaining power of a captive, vulnerable audience.